Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19

Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xi, Jia, Chen, Wu, Jianyong, Zhang, Jian, Jiang, Zhijie, Ma, Kuifen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250997/
https://www.ncbi.nlm.nih.gov/pubmed/35795188
http://dx.doi.org/10.3389/fcimb.2022.916012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250997/
https://www.ncbi.nlm.nih.gov/pubmed/35795188
http://dx.doi.org/10.3389/fcimb.2022.916012

Ejemplares similares